Rare Diseases Global Market Report 2024-2034: Robust Pipeline by Major Players and Increasing Number of Drug Approvals
July 02, 2024 04:01 ET
|
Research and Markets
Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Rare Diseases Market is forecast to...
Registrations Open for the 2024 Orphan Drugs and Rare Diseases Conference - Boston, MA, United States - October 17-18th, 2024
June 28, 2024 10:26 ET
|
Research and Markets
Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases" conference has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and Rare Diseases Conference...
Global $38.9 Billion Medical Food Market by Category, Type, Form, Distribution Channel, Application, and Region - Forecast to 2030
June 21, 2024 09:15 ET
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Food Market 2024-2030" report has been added to ResearchAndMarkets.com's offering.The Medical Food Market size was estimated at USD...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 22, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...
Global Orphan Drug Sector Poised for Growth Amidst Unmet Rare Disease Needs
April 05, 2024 04:04 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study provides critical insights into the...
Rare Disease Treatment Market to Achieve USD 228.34 Billion by 2028, Showcasing a Compound Annual Growth Rate of 11.08%
February 02, 2024 10:52 ET
|
Research and Markets
Dublin, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The "Global Rare Disease Treatment Market (2023-2028) by Therapeutic Area, Drug Type, Drug Class, Mode of Administration, Distribution Channel, and...
Global Orphan Drugs Research Analysis Report 2023: Growing Approvals of Innovative Orphan Drugs Propel Market Expansion, Biologics Lead the Way - Forecasts to 2034
January 31, 2024 11:22 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drugs Market Analysis & Forecast 2024-2034: Market By Drug Type; By Therapy; By Distribution Channel; and By Region" report has been...
Paroxysmal Nocturnal Hemoglobinuria Treatment Advances with Comprehensive Danicopan Market Forecast to 2032
January 24, 2024 10:44 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global healthcare...